---
title: "PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm"
description: "Bragar Eagel & Squire, P.C. is investigating Praxis Precision Medicines, Inc. on behalf of stockholders who may have suffered losses. The investigation focuses on potential violations of federal secur"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254281372.md"
published_at: "2025-08-23T14:33:23.000Z"
---

# PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm

> Bragar Eagel & Squire, P.C. is investigating Praxis Precision Medicines, Inc. on behalf of stockholders who may have suffered losses. The investigation focuses on potential violations of federal securities laws following Praxis's Q2 2025 financial results, which revealed adverse events in a study of its anti-seizure medication, leading to a 5.55% drop in stock price. Investors are encouraged to contact the firm for legal options.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Praxis ( PRAX ) To Contact Him Directly To Discuss Their Options

### Related Stocks

- [PRAX.US - Praxis Precision Medicines](https://longbridge.com/en/quote/PRAX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Praxis Precision Medicines 根據 2024 年激勵計劃向新員工授予限制性股票單位 | Praxis Precision Medicines Inc. 已向八名新非執行員工授予 2,964 個限制性股票單位，作為其 2024 年誘導計劃的一部分。該獎勵將分四個相等的年度分期解鎖，前提是員工繼續在職。此公告通過 GlobeNew | [Link](https://longbridge.com/en/news/274864935.md) |
| Praxis Precision Medicines 在出售 5.75 億美元股票後股價小幅下跌 | Praxis Precision Medicines 的股價下跌 0.5%，至 271.50 美元，此前公司進行了一筆 5.75 億美元的股票出售，約 220 萬股以 4.4% 的折扣出售。公司計劃將所得款項用於晚期產品的商業化和研發。儘管 | [Link](https://longbridge.com/en/news/271799539.md) |
| 券商一致推薦 Praxis Precision Medicines, Inc.（納斯達克股票代碼：PRAX）為 “適度買入” | Praxis Precision Medicines, Inc.（納斯達克代碼：PRAX）獲得了十八家研究公司的 “適度買入” 共識評級。平均 12 個月目標價為 436.67 美元，其中兩位分析師建議賣出，十三位建議買入，三位建議強烈買入 | [Link](https://longbridge.com/en/news/272508104.md) |
| Praxis Precision Medicines 在最新的發佈中重點介紹了其中樞神經系統藥物研發管線及商業策略 | Praxis Precision Medicines Inc. 更新了其晚期中樞神經系統藥物管線，重點介紹瞭如 ulixacaltamide 用於特發性震顫和 relutrigine 用於難治性癲癇發作（DEEs）的療法。該公司報告了一些候 | [Link](https://longbridge.com/en/news/272275638.md) |
| 弗吉尼亞退休系統等機構在 Praxis Precision Medicines, Inc. $PRAX 中建立了價值 207,000 美元的頭寸 | 維吉尼亞退休系統等在第三季度新建了對 Praxis Precision Medicines, Inc.（納斯達克代碼：PRAX）的持倉，購買了 3,900 股，價值約為 207,000 美元。其他機構投資者也調整了他們在該公司的股份。分析師 | [Link](https://longbridge.com/en/news/271797284.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.